Dana-Farber Cancer Institute (Boston) is using Oracle Healthcare Transaction Base (HTB) and Oracle Fusion Middleware components as the foundation for its new translational research infrastructure.
According to Oracle (Redwood Shores, Calif.), the new infrastructure is designed to maximize the value of clinical and research data, and help improve disease understanding and patient care. The new data infrastructure will help researchers investigate clinical data more thoroughly, make complex queries and more complete data analysis, and improve experiment design, touts Oracle.
Using Oracle HTB, Dana-Farber created an integrated data repository that enables researchers to access clinical and sample data using a single platform and seamlessly connect it with experimental data, says the company.
Get the latest information on Health IT and attend other valuable sessions at this two-day Summit providing healthcare leaders with educational content, insightful debate and dialogue on the future of healthcare and technology.